Kukje Pharma Co., Ltd. (KRX:002720)
4,995.00
-15.00 (-0.30%)
Feb 20, 2025, 9:00 AM KST
Kukje Pharma Revenue
Kukje Pharma had revenue of 39.65B KRW in the quarter ending September 30, 2024, with 23.43% growth. This brings the company's revenue in the last twelve months to 150.12B, up 14.59% year-over-year. In the year 2023, Kukje Pharma had annual revenue of 135.37B with 6.94% growth.
Revenue (ttm)
150.12B
Revenue Growth
+14.59%
P/S Ratio
0.68
Revenue / Employee
615.26M
Employees
244
Market Cap
102.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 135.37B | 8.79B | 6.94% |
Dec 31, 2022 | 126.58B | 6.84B | 5.71% |
Dec 31, 2021 | 119.75B | -10.65B | -8.17% |
Dec 31, 2020 | 130.39B | 19.27B | 17.34% |
Dec 31, 2019 | 111.12B | 3.44B | 3.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Hanmi Science | 1,283.65B |
Hanall Biopharma | 134.24B |